References
- Reid CM, Martin RM, Sterne JA, Davies AN, Hanks GW. Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:837-43. https://doi.org/10.1001/archinte.166.8.837
- Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012;26:50-60. https://doi.org/10.1177/0269216311418869
- Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K. Oral naloxone reverses opioid-associated constipation. Pain 2000;84:105-9. https://doi.org/10.1016/S0304-3959(99)00185-2
- Smith K, Hopp M, Mundin G, Bond S, Bailey P, Woodward J, et al. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther 2012;50:360-7. https://doi.org/10.5414/CP201646
- Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf 2018;9:63-88. https://doi.org/10.1177/2042098617744161
- Wong A, Macleod D, Robinson J, Koutsogiannis Z, Graudins A, Greene SL. Oxycodone/naloxone preparation can cause acute withdrawal symptoms when misused parenterally or taken orally. Clin Toxicol (Phila) 2015;53:815-8. https://doi.org/10.3109/15563650.2015.1060486
- Kim JH, Song H, Lee G-W, Kang JH. Opioid withdrawal symptoms after conversion to oral oxycodone/naloxone in advanced cancer patients receiving strong opioids. Korean J Hosp Palliat Care 2017;20:131-5. https://doi.org/10.14475/kjhpc.2017.20.2.131
- Kang JH, Lee GW, Shin SH, Bruera E. Opioid withdrawal syndrome after treatment with low-dose extended-release oxycodone and naloxone in a gastric cancer patient with portal vein thrombosis. J Pain Symptom Manage 2013;46:e15-7. https://doi.org/10.1016/j.jpainsymman.2013.02.009
- Vanden Hoek TL, Morrison LJ, Shuster M, Donnino M, Sinz E, Lavonas EJ, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010;122:S829-61. https://doi.org/10.1161/CIRCULATIONAHA.110.971069
- Bellingan M. What drug?: Naloxone. Australian Pharmacist 2017;36:54-7.
- Pergolizzi JV Jr, Raffa RB, Rosenblatt MH. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management. J Clin Pharm Ther 2020;45:892-903. https://doi.org/10.1111/jcpt.13114
- Yu E, Miotto K, Akerele E, Montgomery A, Elkashef A, Walsh R, et al. A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. Drug Alcohol Depend 2008;97:158-68. https://doi.org/10.1016/j.drugalcdep.2008.04.002
- Gowing L, Farrell MF, Ali R, White JM. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2014;CD002024.
- Jung S, Rosini JM. Dexmedetomidine for treatment of refractory heroin withdrawal. J Emerg Nurs 2017;43:182-4. https://doi.org/10.1016/j.jen.2017.01.004